Functional analysis of naturally occurring mutations in the open reading frame of CCR5 in HIV-infected Chinese patients and healthy controls

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 5, 2005, Pages 509-517

  Zhao, Xiu Ying ^a   Lee, Shui Shan ^b   Wong, Ka Hing ^b   Chan, Kenny C W ^b   Ng, Fai ^a   Chan, Chris C S ^a   Han, Dan ^a   Yam, Wing Cheong ^a   Yuen, Kwok Yung ^a   Ng, Mun Hon ^a   Zheng, Bo Jian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

CCR5 polymorphism; Coreceptor function; Disease progression; Expression and conformation; HIV infection

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CCR5; GLUTAMINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CHINESE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISEASE COURSE; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MOLECULAR CLONING; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; GENE FREQUENCY; HIV INFECTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; OPEN READING FRAMES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; RECEPTORS, CCR5; REFERENCE VALUES; TRANSCRIPTION, GENETIC;

EID: 20244365650     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000151004.19128.4a     Document Type: Article

References (62)

1. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667-673.
2. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
3. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955-1958.
4. Alkhatib G, Liao F, Berger EA, et al. A new SIV co-receptor, STRL33. Nature. 1997;388:238.
5. Raja A, Venturi M, Kwong P, et al. CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol. 2003;77:713-718.
6. Broder CC, Collman RG. Chemokine receptors and HIV J Leukoc Biol. 1997;62:20-29.
7. Weiss RA. HIV receptors and the pathogenesis of AIDS. Science. 1996; 272:1885-1886.
8. Cheng-Mayer C, Liu R, Landau NR, et al. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol. 1997;71:1657-1661.
9. Liao F, Alkhatib G, Peden KW, et al. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med. 1997;185:2015-2023.
10. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997;385:645-649.
11. Lee S, Tiffany HL, King L, et al. CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. J Virol. 2000;74: 6946-6952.
12. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996;85:1149-1158.
13. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-877.
14. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol. 1996;70:5487-5494.
15. Atchison RE, Gosling J, Monteclaro FS, et al. Multiple extracellular elements of CCR5 and HTV-1 entry: dissociation from response to chemokines. Science. 1996;274:1924-1926.
16. Edinger AL, Amedee A, Miller K, et al. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci USA. 1997;94:4005-4010.
17. Lu Z, Berson JF, Chen Y, et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA. 1997;94:6426-6431.
18. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS. 1997;11(Suppl A):S3-S16.
19. Blanpain C, Libert F, Vassart G, et al. CCR5 and HIV infection. Receptors Channels. 2002;8:19-31.
20. Blanpain C, Lee B, Vakili J, et al. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem. 1999;274:18902-18908.
21. Carrington M, Dean M, Martin MP, et al. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet. 1999;8:1939-1945.
22. Doranz BJ, Lu ZH, Rucker J, et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol. 1997;71:6305-6314.
23. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
24. Combadiere C, Ahuja SK, Tiffany HL, et al. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol. 1996;60:147-152.
25. Zhao XY, Lee SS, Wong KH, et al. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur J Immunogenet. 2004;31:179-183.
26. Zheng BJ, Zhao XY, Zhu NS, et al. Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. AIDS. 2002;16:2480-2482.
27. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 1998;351:14-18.
28. Carrington M, Kissner T, Gerrard B, et al. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet. 1997;61:1261-1267.
29. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA. 2001; 98:5199-5204.
30. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS. 2003;17:377-387.
31. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997; 277:959-965.
32. Ansari-Lari MA, Liu XM, Metzker ML, et al. The extent of genetic variation in the CCR5 gene. Nat Genet. 1997;16:221-222.
33. Kageyama S, Mimaya J, Yamada K, et al. Polymorphism of CCR5 affecting HIV disease progression in the Japanese population. AIDS Res Hum Retroviruses. 2001;17:991-995.
34. Blanpain C, Doranz BJ, Vakili J, et al. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem. 1999; 274:34719-34727.
35. Cecilia D, Kleeberger C, Munoz A, et al. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis. 1999;179:1365-1374.
36. Kostrikis LG, Neumann AU, Thomson B, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol. 1999;73:10264-10271.
37. Dey BBE. Vaccinia-based reporter gene cell-fusion assay to quantitate functional interactions of HIV envelope glycoprotein with receptors. In: Coligan JE, ed. Current Protocols in Immunology. New York: John Wiley & Sons; 2003:12.10.20-12.10.03.
38. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999;96:667-676.
39. Morgenstern JP, Land H. A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res. 1990;18:1068-1107.
40. Romano JW, Shurtliff RN, Lee EM, et al. RANTES and MIP-1beta mRNA expression in human peripheral blood mononuclear cells: transcript quantification using NASBA technology. J Immunol Methods. 2001;255:115-124.
41. Zhao XY, Lee SS, Wong KH, et al. A novel CCR5 mutation selectively affects immunoreactivity and fusogenic property of the HIV co-receptor. AIDS. 2004;18:1729-1732.
42. Fuerst TR, Niles EG, Studier FW, et al. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA. 1986;83:8122-8126.
43. Jin X, Ramanathan M, Jr, Barsoum S, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol. 2002;76:2206-2216.
44. Cameron PU, Hunter SD, Jolley D, et al. Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects. Cytometry. 1998;33:83-88.
45. Alkhatib G, Ahuja SS, Light D, et al. CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion. J Biol Chem. 1997;272:19771-19776.
46. Blanpain C, Doranz BJ, Bondue A, et al. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem. 2003;278:5179-5187.
47. Aarons EJ, Beddows S, Willingham T, et al. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology. 2001;287:382-390.
48. Mirzabekov T, Bannert N, Farzan M, et al. Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor. J Biol Chem. 1999;274:28745-28750.
49. Wu L, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186:1373-1381.
50. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood. 1998;92:3105-3114.
51. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996; 271:324-328.
52. Levy JA, Scott I, Mackewicz C. Protection from HIV/AIDS: the importance of innate immunity. Clin Immunol. 2003;108:167-174.
53. Boaz MJ, Waters A, Murad S, et al. CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects. Clin Exp Immunol. 2003;134: 454-463.
54. Lopalco L. Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? Curr HIV Res. 2004;2:127-139.
55. Romiti ML, Colognesi C, Cancrini C, et al. Prognostic value of a CCR5 defective allele in pediatric HIV-1 infection. Mol Med. 2000;6: 28-36.
56. Shioda T, Nakayama EE, Tanaka Y, et al. Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol. 2001;75:3462-3468.
57. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
58. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS. 1997; 11:1833-1838.
59. Sullivan AD, Wigginton J, Kirschner D. The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV Proc Natl Acad Sci USA. 2001;98:10214-10219.
60. Govaerts C, Blanpain C, Deupi X, et al. The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem. 2001;276:13217-13225.
61. Farzan M, Choe H, Vaca L, et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998; 72:1160-1164.
62. Lee B, Sharron M, Blanpain C, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem. 1999;274:9617-9626.